Do you recall GILD releasing SVR4 rates for either the POSITRON or FISSION studies?
I only remember SVR4 data for the ELECTRON study and AI444040 Study (the sofo+dacla trial) at AASLD. As for the POSITRON trial, there's this paragraph in the PR:
All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.
This implies that the reason for relapsing is not resistance as there was no virologic breakthrough on-treatment and sequencing from erlier trials didn't identify any S282T-containing mutants in relapsers. I think that with interferon-free regimens clearing the virus is the problem and focus is more on possible late relapse as seen in ABT’s PILOT trial and in BI’s SOUND-C2 trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.